355 related articles for article (PubMed ID: 31040850)
1. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
Palatnik-de-Sousa CB
Front Immunol; 2019; 10():813. PubMed ID: 31040850
[TBL] [Abstract][Full Text] [Related]
2. The F1F3 Recombinant Chimera of
Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
Front Immunol; 2019; 10():724. PubMed ID: 31024556
[No Abstract] [Full Text] [Related]
3. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
Front Immunol; 2018; 9():967. PubMed ID: 29867949
[TBL] [Abstract][Full Text] [Related]
4. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the
Alves-Silva MV; Nico D; Morrot A; Palatnik M; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():100. PubMed ID: 28280494
[TBL] [Abstract][Full Text] [Related]
5. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.
Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB
PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470
[TBL] [Abstract][Full Text] [Related]
6. Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.
Nico D; Gomes DC; Alves-Silva MV; Freitas EO; Morrot A; Bahia D; Palatnik M; Rodrigues MM; Palatnik-de-Sousa CB
Front Immunol; 2014; 5():189. PubMed ID: 24822054
[TBL] [Abstract][Full Text] [Related]
7.
Barbosa Santos ML; Nico D; de Oliveira FA; Barreto AS; Palatnik-de-Sousa I; Carrillo E; Moreno J; de Luca PM; Morrot A; Rosa DS; Palatnik M; Bani-Corrêa C; de Almeida RP; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():227. PubMed ID: 28321221
[TBL] [Abstract][Full Text] [Related]
8. F1 Domain of the
Carrillo E; Fernandez L; Ibarra-Meneses AV; Santos MLB; Nico D; de Luca PM; Correa CB; de Almeida RP; Moreno J; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():750. PubMed ID: 28747911
[TBL] [Abstract][Full Text] [Related]
9. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
[TBL] [Abstract][Full Text] [Related]
10. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
[TBL] [Abstract][Full Text] [Related]
11. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis.
Borja-Cabrera GP; Santos FB; Picillo E; Gravino AE; Manna L; Palatnik-de-Sousa CB
Procedia Vaccinol; 2009; 1(1):104-109. PubMed ID: 32288909
[TBL] [Abstract][Full Text] [Related]
13. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.
Nico D; Gomes DC; Palatnik-de-Sousa I; Morrot A; Palatnik M; Palatnik-de-Sousa CB
Front Immunol; 2014; 5():273. PubMed ID: 24966857
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
[TBL] [Abstract][Full Text] [Related]
16. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
18. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
[TBL] [Abstract][Full Text] [Related]
20. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
Kashyap M; Jaiswal V; Farooq U
Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
